GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc covers the month of March 2025, with a report date of March 28, 2025. The document serves as a transaction notification regarding the release of American Depositary Shares (ADSs) to four Senior Independent Non-Executive Directors following the termination of the GSK Non-Executive Director Share Allocation Arrangements.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on specific equity transactions involving directors.
| Transaction Date | Instrument | Price per ADS | Total ADSs Released |
|---|---|---|---|
| 2025-03-25 | ADSs (ISIN: US37733W2044) | $38.805 | 24,505 |
Breakdown by Director:
- Charles Bancroft: 15,843 ADSs released (1,602 withheld for tax); residual cash payment of $32.60.
- Dr. Anne Beal: 970 ADSs released (1,018 withheld for tax); residual cash payment of $4.66.
- Dr. Hal Dietz: 850 ADSs released (909 withheld for tax); residual cash payment of $38.42.
- Dr. Jesse Goodman: 6,842 ADSs released (7,082 withheld for tax); residual cash payment of $11.64.
Material Changes
The filing reports the finalization of share allocation arrangements for the named directors. The ADSs released are to be held by the respective directors until their retirement from the Board. There are no material changes to the company's operational or financial status reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies related to the company's business operations. It is a regulatory disclosure of director share transactions executed on the New York Stock Exchange (XNYS).
Investor Verification Points
- Verify the total number of ADSs released to directors (24,505) against the company's insider trading reports.
- Confirm the transaction price of $38.805 per ADS aligns with the market price on March 25, 2025.
- Note that the released shares are subject to holding restrictions until the directors retire from the Board.
- Understand that this filing does not reflect the company's quarterly or annual financial performance.